116 related articles for article (PubMed ID: 15531454)
1. Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms.
Fernàndez V; Jares P; Beà S; Salaverria I; Guino E; de Sanjosé S; Colomer D; Ott G; Montserrat E; Campo E
Haematologica; 2004 Nov; 89(11):1322-31. PubMed ID: 15531454
[TBL] [Abstract][Full Text] [Related]
2. The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas.
Paterson JC; Tedoldi S; Craxton A; Jones M; Hansmann ML; Collins G; Roberton H; Natkunam Y; Pileri S; Campo E; Clark EA; Mason DY; Marafioti T
Haematologica; 2006 Jun; 91(6):772-80. PubMed ID: 16769579
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
Pérez-Chacón G; Contreras-Martín B; Cuní S; Rosado S; Martín-Donaire T; Losada-Fernández I; Vargas JA; Jordá J; Alvarez N; García-Marco J; Pérez-Aciego P
Am J Clin Pathol; 2005 May; 123(5):646-50. PubMed ID: 15981803
[TBL] [Abstract][Full Text] [Related]
4. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma.
Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Kang CS; Kim KM; Jang JJ; Nam SW; Lee JY; Yoo NJ
Oncogene; 2001 Jan; 20(3):399-403. PubMed ID: 11313970
[TBL] [Abstract][Full Text] [Related]
7. Death receptor 4 and bladder cancer risk.
Hazra A; Chamberlain RM; Grossman HB; Zhu Y; Spitz MR; Wu X
Cancer Res; 2003 Mar; 63(6):1157-9. PubMed ID: 12649168
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in the tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) do not contribute but Death Receptor (DR4) genes may contribute to susceptibility to head and neck cancer in Pakistani population.
Sarwar R; Mansoor Q; Farooqi AA; Shahzad S; Fayyaz S; Ismail M
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):53-6. PubMed ID: 26718429
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
10. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Jang JJ; Han JY; Lee JY; Yoo NJ
Cancer Res; 1999 Nov; 59(22):5683-6. PubMed ID: 10582684
[TBL] [Abstract][Full Text] [Related]
11. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction.
Koornstra JJ; Jalving M; Rijcken FE; Westra J; Zwart N; Hollema H; de Vries EG; Hofstra RW; Plukker JT; de Jong S; Kleibeuker JH
Eur J Cancer; 2005 May; 41(8):1195-202. PubMed ID: 15911244
[TBL] [Abstract][Full Text] [Related]
12. Rare loss-of-function mutation of a death receptor gene in head and neck cancer.
Pai SI; Wu GS; Ozören N; Wu L; Jen J; Sidransky D; El-Deiry WS
Cancer Res; 1998 Aug; 58(16):3513-8. PubMed ID: 9721851
[TBL] [Abstract][Full Text] [Related]
13. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
14. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity.
Adams J; Cuthbert-Heavens D; Bass S; Knowles MA
Cancer Lett; 2005 Apr; 220(2):137-44. PubMed ID: 15766588
[TBL] [Abstract][Full Text] [Related]
15. Deletions at 11q23 in different lymphoma subtypes.
Zhu Y; Monni O; Franssila K; Elonen E; Vilpo J; Joensuu H; Knuutila S
Haematologica; 2000 Sep; 85(9):908-12. PubMed ID: 10980627
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer.
Fisher MJ; Virmani AK; Wu L; Aplenc R; Harper JC; Powell SM; Rebbeck TR; Sidransky D; Gazdar AF; El-Deiry WS
Clin Cancer Res; 2001 Jun; 7(6):1688-97. PubMed ID: 11410508
[TBL] [Abstract][Full Text] [Related]
17. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
18. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
[TBL] [Abstract][Full Text] [Related]
19. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
van der Sloot AM; Tur V; Szegezdi E; Mullally MM; Cool RH; Samali A; Serrano L; Quax WJ
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8634-9. PubMed ID: 16731632
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability analysis in typical and progressed mantle cell lymphoma and B-cell chronic lymphocytic leukemia.
Sanz-Vaqué L; Colomer D; Bosch F; López-Guillermo A; Dreyling MH; Bosch F; Montserrat E; Campo E
Haematologica; 2001 Feb; 86(2):181-6. PubMed ID: 11224488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
